Persistent Symptoms in Patients Recovering From COVID-19 in Denmark.
COVID-19
SARS-CoV-2
post-COVID-19
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
28
12
2020
accepted:
24
01
2021
entrez:
20
4
2021
pubmed:
21
4
2021
medline:
21
4
2021
Statut:
epublish
Résumé
Although persistent symptoms after coronavirus disease 2019 (COVID-19) are emerging as a major complication to the infection, data on the diversity and duration of symptoms are needed. Patients aged ≥18 years with a positive polymerase chain reaction (PCR) test for severe acute respiratory syndrome coronavirus 2 who were hospitalized at the Department of Infectious Diseases, Aarhus University Hospital, Denmark, in the period from March 11 to May 15 were offered follow-up after hospitalization. On admission, a comprehensive symptom and medical history was collected, including demographic characteristics, duration of symptoms, comorbidities, and concomitant medications. At discharge, patients were offered follow-up consultations-either by telephone or at an in-person visit-at 6 and 12 weeks at our post-COVID-19 outpatient clinic to assess whether symptoms present at admission had resolved. During the inclusion period, 71 patients were admitted with COVID-19. Of these, 10 patients died, 3 were transferred to another region, 4 declined to participate, and 5 were lost to follow-up before the 12-week evaluation. Thus, 49 patients were included. Overall, 96% reported 1 or more persisting symptoms at 12-week follow-up. The main symptoms were fatigue, dyspnea, cough, chemosensory dysfunction, and headache. A wide range of persistent symptoms in patients recovering from COVID-19 were present 12 weeks after hospitalization, calling for larger descriptive studies and interdisciplinary research collaborations.
Sections du résumé
BACKGROUND
BACKGROUND
Although persistent symptoms after coronavirus disease 2019 (COVID-19) are emerging as a major complication to the infection, data on the diversity and duration of symptoms are needed.
METHODS
METHODS
Patients aged ≥18 years with a positive polymerase chain reaction (PCR) test for severe acute respiratory syndrome coronavirus 2 who were hospitalized at the Department of Infectious Diseases, Aarhus University Hospital, Denmark, in the period from March 11 to May 15 were offered follow-up after hospitalization. On admission, a comprehensive symptom and medical history was collected, including demographic characteristics, duration of symptoms, comorbidities, and concomitant medications. At discharge, patients were offered follow-up consultations-either by telephone or at an in-person visit-at 6 and 12 weeks at our post-COVID-19 outpatient clinic to assess whether symptoms present at admission had resolved.
RESULTS
RESULTS
During the inclusion period, 71 patients were admitted with COVID-19. Of these, 10 patients died, 3 were transferred to another region, 4 declined to participate, and 5 were lost to follow-up before the 12-week evaluation. Thus, 49 patients were included. Overall, 96% reported 1 or more persisting symptoms at 12-week follow-up. The main symptoms were fatigue, dyspnea, cough, chemosensory dysfunction, and headache.
CONCLUSIONS
CONCLUSIONS
A wide range of persistent symptoms in patients recovering from COVID-19 were present 12 weeks after hospitalization, calling for larger descriptive studies and interdisciplinary research collaborations.
Identifiants
pubmed: 33875970
doi: 10.1093/ofid/ofab042
pii: ofab042
pmc: PMC7928683
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab042Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
JAMA Cardiol. 2020 Nov 1;5(11):1265-1273
pubmed: 32730619
Obesity (Silver Spring). 2020 Oct;28(10):1826-1832
pubmed: 32610364
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998
pubmed: 32167747
EClinicalMedicine. 2020 Aug;25:100463
pubmed: 32838236
Dan Med J. 2020 Aug 1;67(8):
pubmed: 32741438
J Rehabil Med. 2020 May 25;52(5):jrm00063
pubmed: 32449782
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
JAMA Cardiol. 2020 Nov 1;5(11):1281-1285
pubmed: 32730555
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
BMJ. 2020 Oct 23;371:m3862
pubmed: 33097561
JAMA. 2016 Jun 28;315(24):2703-11
pubmed: 27367877
JAMA Neurol. 2020 Aug 1;77(8):1018-1027
pubmed: 32469387
Am J Psychiatry. 1983 Jun;140(6):734-9
pubmed: 6846631
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
JAMA. 2010 Oct 27;304(16):1787-94
pubmed: 20978258
Lancet. 2020 Aug 1;396(10247):320-332
pubmed: 32682491
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
JAMA Cardiol. 2021 Jan 1;6(1):116-118
pubmed: 32915194
Int J Epidemiol. 2020 Oct 1;49(5):1468-1481
pubmed: 32887982
Am J Public Health. 2003 Jun;93(6):994-8
pubmed: 12773367
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Neurol Sci. 2020 May 15;412:116824
pubmed: 32299010
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Virus Res. 2014 Dec 19;194:145-58
pubmed: 25281913
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Respir Res. 2020 Jun 29;21(1):163
pubmed: 32600344
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202